

Jan van Amstel

Chairman of the Board
Dutch MS Association



Fampyra and Real World Data in the Netherlands (1)

2016 – 2018

Provisional reimbursement.

2018

Decision Minister of Health

- Stop reimbursement.
- Fampyra is not effective.



2019

Advocacy

- Neurologists have 2 years of positive experiences in prescribing Fampyra.
- Real World Data show improvements in walking ability and cognition.
- 41.000 signatures to reimburse Fampyra presented to the Parliament.
- Fampyra is not expensive.



Fampyra and Real World Data in the Netherlands (2)

2020

Decision Minister of Health

- Fampyra is effective.
- Reimbursement under the condition of 20% of improvement in walking ability.
- A yearly test is introduced.



2022

Decision Minister of Health

The improvement test is abolished.

Stem cell therapy and good examples abroad (1)



2016 First Dutch patient treated in Sweden.

2017 Dutch MS Association offers 50.000 signatures to Parliament to support stem cell therapy.

2018 Dutch MS Association requires treatment in the Netherlands.



Opposition:

- Neurologists
- Health Care Insurers
- Health Care Research Institute
- Ministry of Health



Stem cell therapy and good examples abroad (2)

2018 – 2022



People with MS go abroad

- Hundreds of patients go to Russia and Mexico for treatment.
- This requires crowdfunding.



Advocacy

- Good practices abroad
- If it works abroad, it will work in the Netherlands
- Avoid crowdfunding
- Better aftercare in the Netherlands

2022

Reimbursement for stem cell therapy from basic insurance